MedTrace Logo

Early Treatment for Acute ACL Tear

NCT01692756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2018-12-05

Study results available
· View outcomes & findings →

Summary

This research study is the first of its kind and will allow health care professionals and researchers to answer many questions about the reasons why anterior cruciate ligament (ACL) injury leads to knee pain and disability and osteoarthritis. We also hope that this study will be the beginning of new, more powerful and safer drugs to help patients with ACL injuries heal sooner and return to sports or daily activities pain free. Study participants will be recruited from the University of Kentucky and Vanderbilt University.

The purpose of this research is to gather information on how safe and effective Kenalog® is in alleviating knee pain following ACL rupture.

Conditions

  • Anterior Cruciate Ligament (ACL) Tears

Interventions

DRUG

Kenalog or placebo

DRUG

Kenalog then Placebo

DRUG

Kenalog

DRUG

Placebo

Sponsors & Collaborators

  • Vanderbilt University

    collaborator OTHER

  • Cale Jacobs

    lead OTHER

Principal Investigators

  • Christian Lattermann, MD · University of Kentucky, Department of Orthopaedic Surgery

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
33 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2017-02-05
Completion
2017-02-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01692756 on ClinicalTrials.gov